CClinicalTrials.gg
Not yet recruitingNCT07850492TROP-MASUpdated Sep 30, 2026

High-Sensitivity Troponin T Kinetics and 30-Day Outcomes After Major Abdominal Surgery (TROP-MAS)

An observational study in Myocardial Infarction (MI), Perioperative Myocardial Injury and Sepsis, sponsored by Bach Mai Hospital. Not yet recruiting at 1 site in Vietnam. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Bach Mai Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
650
Ages
45 Years and older
Sex
All
01

Study summary

Major abdominal surgery (MAS) carries a high risk of 30-day mortality (>5%). Perioperative myocardial injury (PMI) and myocardial injury after noncardiac surgery (MINS) frequently develop asymptomatically due to surgical analgesia. The 2022 European Society of Cardiology (ESC) Guidelines recommend routine surveillance with high-sensitivity cardiac troponin (hs-cTn) before and after surgery in high-risk patients, defining PMI by an absolute increase in hs-cTnT >= 14 ng/L or a peak > 5x ULN (> 70 ng/L). However, validation in Asian populations and major abdominal visceral resections is scarce.

This prospective observational cohort study (TROP-MAS) recruits >= 650 consecutive high-cardiovascular-risk patients undergoing major abdominal surgery at Bach Mai Hospital (Hanoi, Vietnam). The study systematically evaluates the incidence and prognostic significance of hs-cTnT kinetics (T0 baseline, T1 24h, T2 48h postoperative) regarding 30-day all-cause mortality, major adverse cardiovascular events (MACE), and severe noncardiac complications (acute kidney injury, sepsis, anastomotic leak, bowel ischemia). Furthermore, it derives and validates population-specific optimal prognostic cut-off values using ROC curve analysis and multivariable Cox modeling.

Read the detailed description
  1. Clinical Rationale and Knowledge Gap:

    Patients with cardiovascular risk undergoing major gastrointestinal, hepatopancreatobiliary, colorectal, or acute abdominal emergency operations experience immense physiological stress. While hs-cTnT is widely accepted as a prognostic biomarker, data specifically delineating the correlation between hs-cTnT elevation and severe surgical/infectious complications (such as anastomotic dehiscence, bowel gangrene, and septic shock) remain sparse. Evidence suggests that microvascular myocardial necrosis and systemic hyperinflammation share common endothelial and microcirculatory pathophysiological pathways.

  2. Biomarker Sampling Schedule:

    • T0: Baseline preoperative hs-cTnT drawn within 24 hours prior to surgery.
    • T1: Postoperative 24 hours (± 6h).
    • T2: Postoperative 48 hours (± 6h).
    • Additional measurements (Tx) performed upon clinical indication (new ECG ischemia, hypotension, unexplained arrhythmia).
  3. Core Diagnostic Definitions:

    • ESC 2022 PMI: Delta hs-cTnT >= 14 ng/L (calculated as Peak(T1, T2) - T0, or \|T2 - T1\|) OR any postoperative peak concentration >= 70 ng/L (> 5x ULN, Roche Cobas Elecsys STAT assay).
    • Myocardial Ischemia Symptoms/Signs: Sensed within 24h of troponin elevation: chest/neck/jaw/arm discomfort, dyspnea, pulmonary edema, ischemic ECG shifts (>= 1 mm ST depression, symmetric T-wave inversion, pathological Q waves, new LBBB), or new wall motion abnormalities on transthoracic echocardiography.
  4. Follow-up Protocol:

Triangulated 30-day follow-up:

  • Complete in-hospital record tracking until discharge.
  • Structured telephone interview conducted at Day 30 ± 3 days post-surgery.
  • Cross-verification with Bach Mai Hospital Electronic Medical Record (EMR/HIS) system.
02

Conditions studied

  • Myocardial Infarction (MI)
  • Perioperative Myocardial Injury
  • Sepsis
  • Digestive System Surgical Procedures
  • Acute Kidney Injury
  • Postoperative Complication
  • Heart Injuries

Keywords

  • High-sensitivity cardiac troponin T
  • hs-cTnT
  • Perioperative myocardial injury
  • PMI
  • Major abdominal surgery
  • Cardiovascular risk
  • 30-day mortality
  • ESC Guidelines
  • RCRI
03

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult surgical patients with established or potential cardiovascular risk scheduled for or undergoing major abdominal surgery under general anesthesia at Bach Mai Hospital.

Inclusion criteria

  • Scheduled for or undergoing elective, urgent, or emergency major abdominal surgery (pancreatectomy, liver resection, gastrectomy, colorectal surgery, or emergency laparotomy) with expected duration >= 2 hours or major visceral resection.
  • Possessing established or potential cardiovascular risk defined by meeting AT LEAST ONE of the following:

    • Age >= 65 years; OR
    • Age 45 to 64 years with at least one documented cardiovascular risk factor or comorbidity: documented coronary artery disease, congestive heart failure, prior ischemic stroke or TIA, peripheral arterial disease (resting ABI \<= 0.90), diabetes mellitus requiring treatment, arterial hypertension, dyslipidemia/hypercholesterolemia, active cigarette smoking, overweight/obesity (BMI >= 25 kg/m\^2), family history of premature cardiovascular disease, unexplained cardiac signs/symptoms, chronic obstructive pulmonary disease (COPD), baseline chronic renal impairment (eGFR \< 60 mL/min/1.73m\^2 or serum creatinine > 177 umol/L), or Revised Cardiac Risk Index (RCRI) >= 2 points.
  • Signed Informed Consent Form permitting electronic medical record (EMR) data extraction and participation in a 30-day follow-up telephone interview.

Exclusion criteria

Exclusion Criteria:

  • Active acute myocardial infarction or acute coronary syndrome within 30 days prior to the index surgical procedure.
  • End-stage renal disease (ESRD) on maintenance hemodialysis or peritoneal dialysis.
  • Intraoperative mortality or death within the first 24 hours postoperatively due to acute massive surgical exsanguination.
  • Incomplete postoperative troponin testing protocol (missing both 24h and 48h postoperative blood samples).
  • Patient or legal surrogate withdrawal of consent during the 30-day surveillance period.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
650 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cohort A (PMI)

    Patients who develop Perioperative Myocardial Injury (PMI) defined according to the 2022 ESC Guidelines: absolute delta increase in hs-cTnT \>= 14 ng/L above baseline or between postoperative 24h and 48h, OR any postoperative peak hs-cTnT concentration \>= 70 ng/L.

    Diagnostic Test: High-sensitivity cardiac troponin T (hs-cTnT) surveillance

  • Cohort B (Non-PMI)

    Patients who undergo major abdominal surgery with cardiovascular risk but do not meet the criteria for PMI (delta increase \< 14 ng/L and peak hs-cTnT \< 70 ng/L).

    Diagnostic Test: High-sensitivity cardiac troponin T (hs-cTnT) surveillance

Interventions

  • Diagnostic testHigh-sensitivity cardiac troponin T (hs-cTnT) surveillance

    Serial blood sampling for high-sensitivity cardiac troponin T (hs-cTnT) measurement using the Roche Cobas Elecsys STAT assay: preoperatively within 24 hours before incision (T0), at 24 hours (± 6h) postoperatively (T1), and at 48 hours (± 6h) postoperatively (T2). Additional samples are obtained if ischemic symptoms or signs occur.

05

What researchers measure

Primary outcomes

  1. Incidence of Perioperative Myocardial Injury (PMI)

    Occurrence of Perioperative Myocardial Injury (PMI) defined according to the 2022 ESC Guidelines as an absolute delta increase in high-sensitivity cardiac troponin T (Delta hs-cTnT \>= 14 ng/L) from preoperative baseline to postoperative 24h or 48h (or between postoperative 24h and 48h), OR any postoperative peak hs-cTnT concentration \>= 70 ng/L (\> 5x ULN, Roche Cobas Elecsys STAT assay).

    Time frame: Within 48 hours postoperatively

  2. All-Cause Mortality

    Cumulative incidence of all-cause death occurring within 30 days after index major abdominal surgery, verified through hospital records, Electronic Medical Records (EMR), and structured Day 30 telephone interview.

    Time frame: Within 30 days after surgery

Secondary outcomes

  1. Major Adverse Cardiovascular Events (MACE)

    Composite of nonfatal cardiac arrest, nonfatal clinical AMI (Fourth Universal Definition), acute decompensated heart failure, malignant ventricular arrhythmia, and new ischemic/hemorrhagic stroke confirmed by neuroimaging.

    Time frame: 30 days post-surgery

  2. Severe Sepsis and Septic Shock

    Incidence of severe sepsis and septic shock defined by Sepsis-3 Consensus Criteria (infection with acute SOFA increase \>= 2 points; septic shock requiring vasopressors for MAP \>= 65 mmHg with lactate \> 2 mmol/L).

    Time frame: 30 days post-surgery

  3. Major Surgical Complications

    Incidence of Clavien-Dindo Grade \>= III complications (anastomotic leak, acute bowel ischemia, secondary peritonitis, intra-abdominal hemorrhage, and unplanned reoperation).

    Time frame: 30 days post-surgery

  4. Prognostic Accuracy of hs-cTnT Kinetics for 30-Day Composite Major Complications and Mortality

    Discriminative performance measured by Area Under the Receiver Operating Characteristic Curve (AUC / C-statistic) and derivation of optimal population-specific prognostic cut-off thresholds for Peak hs-cTnT and absolute Delta hs-cTnT to predict a 30-day composite major adverse outcome. The composite endpoint encompasses: 1. 30-day all-cause mortality; 2. Major adverse cardiovascular events (MACE: nonfatal cardiac arrest, acute myocardial infarction, acute heart failure, life-threatening arrhythmias, and stroke); 3. Major surgical and intra-abdominal complications (Clavien-Dindo Grade \>= III: gastrointestinal anastomotic leak/dehiscence, acute mesenteric/intestinal ischemia or gangrene, secondary peritonitis, intra-abdominal hemorrhage, and unplanned reoperation); 4. Severe non-cardiac complications (severe sepsis, septic shock by Sepsis-3 criteria, and acute kidney injury KDIGO Stage 2-3).

    Time frame: Within 30 days post-surgery

  5. Length of ICU and Hospital Stay

    Duration of index postoperative Surgical ICU/PACU stay (days) and total hospital length of stay from surgery to discharge or death.

    Time frame: Up to discharge / 30 days

  6. Acute Kidney Injury (AKI) Postoperative Incidence

    Occurrence and staging of acute kidney injury classified according to KDIGO (Kidney Disease: Improving Global Outcomes) serum creatinine criteria: Stage 1 (increase \>= 26.5 umol/L within 48h or 1.5-1.9 times baseline), Stage 2 (2.0-2.9 times baseline), Stage 3 (\>= 3.0 times baseline or initiation of renal replacement therapy).

    Time frame: During index hospital admission, up to 30 days post-surgery

06

Study locations

1 site
  • Bach Mai Hospital
    Hanoi, Dong Da 100000, Vietnam
07

References and documents

Publications

  • Noordzij PG, van Geffen O, Dijkstra IM, Boerma D, Meinders AJ, Rettig TC, Eefting FD, van Loon D, van de Garde EM, van Dongen EP. High-sensitive cardiac troponin T measurements in prediction of non-cardiac complications after major abdominal surgery. Br J Anaesth. 2015 Jun;114(6):909-18. doi: 10.1093/bja/aev027. Epub 2015 Mar 3. PubMed 25740400 ↗
  • Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I, Geisler T, Hinterbuchner L, Ibanez B, Lenarczyk R, Mansmann UR, McGreavy P, Mueller C, Muneretto C, Niessner A, Potpara TS, Ristic A, Sade LE, Schirmer H, Schupke S, Sillesen H, Skulstad H, Torracca L, Tutarel O, Van Der Meer P, Wojakowski W, Zacharowski K; ESC Scientific Document Group. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022 Oct 14;43(39):3826-3924. doi: 10.1093/eurheartj/ehac270. No abstract available. PubMed 36017553 ↗
  • Writing Committee for the VISION Study Investigators; Devereaux PJ, Biccard BM, Sigamani A, Xavier D, Chan MTV, Srinathan SK, Walsh M, Abraham V, Pearse R, Wang CY, Sessler DI, Kurz A, Szczeklik W, Berwanger O, Villar JC, Malaga G, Garg AX, Chow CK, Ackland G, Patel A, Borges FK, Belley-Cote EP, Duceppe E, Spence J, Tandon V, Williams C, Sapsford RJ, Polanczyk CA, Tiboni M, Alonso-Coello P, Faruqui A, Heels-Ansdell D, Lamy A, Whitlock R, LeManach Y, Roshanov PS, McGillion M, Kavsak P, McQueen MJ, Thabane L, Rodseth RN, Buse GAL, Bhandari M, Garutti I, Jacka MJ, Schunemann HJ, Cortes OL, Coriat P, Dvirnik N, Botto F, Pettit S, Jaffe AS, Guyatt GH. Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. JAMA. 2017 Apr 25;317(16):1642-1651. doi: 10.1001/jama.2017.4360. PubMed 28444280 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in future publications will be available to qualified researchers upon reasonable academic request. Data will be available beginning 6 months and ending 36 months following article publication. Requests should be directed to the Principal Investigator (nguyenbatu@hmu.edu.vn / nguyentoanthang@hmu.edu.vn). To gain access, data requestors will need to provide a methodologically sound research proposal and sign a data access agreement approved by the institutional ethics committee.

Supporting information: Study protocol, Sap

08

Registry details

Key details

Study ID
NCT07850492
Lead sponsor
Bach Mai Hospital
Collaborators
Hanoi Medical University
Responsible party
Nguyen Toan Thang (Associate Professor, Head of Department of Anesthesiology and Intensive Care, Bach Mai Hospital) — Principal investigator
First posted
Sep 30, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Tu Ba Nguyen, MD, MSc
Contact
nguyenbatu@hmu.edu.vn
+84968908819
Thang Toan Nguyen, MD, PhD, Assoc. Prof.
Contact
nguyentoanthang@hmu.edu.vn
+84916874795

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion